ERBB2 and breast carcinoma: Currently, several prognostic biomarkers of breast cancer (e.g., hormone receptor status, HER-2 status, Ki-67 LI, p53 expression, and histologic grade) are considered to be sources of valuable information regarding tumor aggressiveness, as well as the likelihood of response to therapy.